Pushing AR Toward Better Outcomes In Breast And Prostate Cancers
Funder
National Health and Medical Research Council
Funding Amount
$998,754.00
Summary
Breast and prostate cancers kill >6000 Australians each year. These cancers are strikingly similar, both driven by hormone receptors that have ‘gone bad’. Current therapies aim to eradicate the receptors. While often effective, therapeutic resistance is common and results in fatal disease. We aim to develop new, less toxic treatments that switch receptor behaviour from good to bad, without destroying them. This should improve quality of life, while preventing drug resistance and loss of lives ....Breast and prostate cancers kill >6000 Australians each year. These cancers are strikingly similar, both driven by hormone receptors that have ‘gone bad’. Current therapies aim to eradicate the receptors. While often effective, therapeutic resistance is common and results in fatal disease. We aim to develop new, less toxic treatments that switch receptor behaviour from good to bad, without destroying them. This should improve quality of life, while preventing drug resistance and loss of lives.Read moreRead less
The Molecular Basis of Nanoparticle Resistance in Mixed-Species Biofilm. The project aims to understand how the globally significant mixed-species growth of pathogens develop resistance to silver nanoparticle, currently one of the most important alternative antimicrobials to antibiotics. The integrated research is to elucidate, for the first time, the nanoparticle multi-targeting toxicity on mixed-species bacterial community and how, in turn, the bacteria activate their cell-to-cell signalling f ....The Molecular Basis of Nanoparticle Resistance in Mixed-Species Biofilm. The project aims to understand how the globally significant mixed-species growth of pathogens develop resistance to silver nanoparticle, currently one of the most important alternative antimicrobials to antibiotics. The integrated research is to elucidate, for the first time, the nanoparticle multi-targeting toxicity on mixed-species bacterial community and how, in turn, the bacteria activate their cell-to-cell signalling for a synergistic defence to adapt to the nanoparticle toxicity. The pioneering knowledge is the foundation for technologies targeting the interspecies metabolite cross-talking to overcome the resistance phenomena, ensuring a long-term efficacy of the alternative antimicrobial on the difficult-to-control pathogenic growth.Read moreRead less
Reducing health disparities for culturally and linguistically diverse peoples. This project aims to develop a greater understanding of migrants and the factors that predict poor health outcomes related to blood-borne viruses and sexually transmitted infections. The delayed access by migrants to healthcare from culturally and linguistically diverse backgrounds results in late diagnosis, low treatment uptake, and poorer health outcomes, with enhanced risk of infection and increased burden on the h ....Reducing health disparities for culturally and linguistically diverse peoples. This project aims to develop a greater understanding of migrants and the factors that predict poor health outcomes related to blood-borne viruses and sexually transmitted infections. The delayed access by migrants to healthcare from culturally and linguistically diverse backgrounds results in late diagnosis, low treatment uptake, and poorer health outcomes, with enhanced risk of infection and increased burden on the health system. The data collected in this project will assist in developing health services to meet these needs.Read moreRead less
The unfolding story of the 2009 Adelaide heatwave: risk factors for mortality and morbidity. This project will conduct a case control study in Adelaide to explore the risk factors of extra health burden related to the 2009 heatwave. Given the prediction of more extreme heat events, this study will provide important information for policy makers and service providers to assist in the development of more resilient communities to climate change.